We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ose Immunotherapeutics Sa | LSE:0RAD | London | Ordinary Share | FR0012127173 | ORPHAN SYNERGY EUROPE IMMUNOTHERAPEUTICS |
Price Change | % Change | Share Price | Bid Price | Offer Price | |
---|---|---|---|---|---|
0.00 | 0.00% | 4.12 |
High Price | Low Price | Open Price | Shares Traded | Last Trade |
---|---|---|---|---|
532 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 2.23M | -23M | -1.0624 | -6.94 | 89.2M |
Date | Time | Source | Headline |
---|---|---|---|
02/12/2024 | 17:00 | UKREG | OSE Immunotherapeutics Strengthens Leadership and Executive Committee |
02/12/2024 | 17:00 | UKREG | OSE Immunotherapeutics Renforce son Équipe de Direction et son Comité.. |
04/11/2024 | 17:00 | UKREG | Informations relatives au nombre total de droits de vote et d’actions.. |
04/11/2024 | 06:30 | UKREG | OSE Immunotherapeutics Annonce des Résultats Cliniquement Probants et.. |
04/11/2024 | 06:30 | UKREG | OSE Immunotherapeutics Announces Statistically Significant and Clinically.. |
17/10/2024 | 16:00 | UKREG | OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology.. |
17/10/2024 | 16:00 | UKREG | OSE Immunotherapeutics présente une nouvelle technologie bispécifique de.. |
02/10/2024 | 16:00 | UKREG | Informations relatives au nombre total de droits de vote et d’actions.. |
26/9/2024 | 16:00 | UKREG | OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides.. |
26/9/2024 | 16:00 | UKREG | OSE Immunotherapeutics annonce des résultats semestriels 2024 remarquables.. |
1 Year Ose Immunotherapeutics Chart |
Intraday Ose Immunotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions